Search Results

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”) today announced that it entered into a collaboration agreement with SIGA Technologies (Nasdaq: SIGA) in the first quarter of 2024, to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.

Calidi Biotherapeutics, Inc. today announced the appointment of Dr. George E. Peoples, MD, FACS, to the company’s Board of Directors, effective July 1, 2024.

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted virotherapies, today reported its first quarter 2024 operating and financial results and reviewed recent business highlights.